John H. Johnson Joins Cancer Therapeutics Specialist Aveo's Board of Directors
6 February 2018 - - Cambridge, Massachusetts-based cancer therapeutics specialist Aveo Oncology (NASDAQ: AVEO) has appointed John H. Johnson to the company's board of directors, the company said.
Johnson has over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at global corporations with a focus on oncology, including Johnson and Johnson, Eli Lilly and company, ImClone Systems, Dendreon, and Pfizer.
Johnson previously served as chairman, president and chief executive officer of Dendreon Corp. and as chief executive officer and on the board of Savient Pharmaceuticals, Inc.
Prior to these roles, he served as president of Eli Lilly and Company's global oncology unit following the company's 2008 acquisition of ImClone Systems Inc., where he served as chief executive officer and on ImClone's board.
Prior to ImClone, Johnson served as the company group chairman of biopharmaceuticals within Johnson and Johnson, where he was responsible for the Johnson and Johnson biotechnology, immunology and oncology commercial businesses.
Prior to that role, he held several executive positions at Johnson and Johnson, Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corp. and Pfizer Inc.
Aveo Oncology is dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need.
The company is focused on development and commercialization of its lead candidate tivozanib as a treatment for renal cell carcinoma and other cancers in North America, and is leveraging multiple partnerships to develop and commercialise tivozanib in oncology indications outside of North America, and at progressing its pipeline of novel therapeutic candidates in cancer and cachexia.